La vendita allo scoperto per Reshape Lifesciences dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Reshape Lifesciences. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Reshape Lifesciences (NASDAQ:RSLS) Azioni, Report sulle vendite allo scoperto

Reshape Lifesciences

Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.

ReShape Lifesciences, Inc. - Common Stock

Reshape Lifesciences Inc

Jefferies analyst Omar Nokta maintains Teekay Tankers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TNK#NYSE">TNK</a>) with a Buy and maintains $55 price target.

News

Price Target

Analyst Ratings

Jefferies Maintains Buy on Teekay Tankers, Maintains $55 Price Target

Needham analyst Ryan Koontz maintains F5 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIV#NASDAQ">FFIV</a>) with a Buy and raises the price target from $320 to $345.

FFIV

Needham Maintains Buy on F5, Raises Price Target to $345

Ferrari (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RACE#NYSE">RACE</a>) reported quarterly earnings of $2.70 per share which beat the analyst consensus estimate of $2.39 by 13.08 percent. This is a 9.23 percent increase over earnings of $2.47 per share from the same period last year. The company reported quarterly sales of $2.03 billion which beat the analyst consensus estimate of $1.82 billion by 11.13 percent. This is a 9.93 percent increase over sales of $1.84 billion the same period last year.

Earnings

Earnings Beats

RACE

Ferrari Q2 EPS $2.70 Beats $2.39 Estimate, Sales $2.03B Beat $1.82B Estimate

<ul>
<li>Mounjaro met the primary objective of non-inferiority vs. Trulicity with an 8% lower rate of MACE-3 events, while delivering greater reductions in A1C and weight</li>
<li>In the trial, Mounjaro was associated with a 16% lower rate of all-cause death compared to Trulicity, suggesting more comprehensive health benefits</li>
<li>Results from the largest and longest Mounjaro trial to date reaffirm its established safety and tolerability profile</li>
</ul>

Biotech

Large Cap

Health Care

General

Eli Lilly Announced Topline Results From SURPASS-CVOT Head-to-head Phase 3 Trial Comparing Mounjaro (Tirzepatide) To Trulicity (Dulaglutide), Mounjaro Achieved The Primary Objective By Demonstrating A Non-inferior Rate Of Major Adverse Cardiovascular Events, Including Cardiovascular Death, Heart Attack Or Stroke Vs. Trulicity

Needham analyst Ryan MacDonald reiterates Udemy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UDMY#NASDAQ">UDMY</a>) with a Buy and maintains $11 price target.

Reiteration

UDMY

Needham Reiterates Buy on Udemy, Maintains $11 Price Target

Guidance

APTV

Aptiv Raises FY2025 Adj EPS Guidance from $7.00-$7.60 to $7.30-$7.60 vs $7.14 Est; Narrows FY2025 Sales Guidance from $19.600B-$20.400B to $20.000B-$20.300B vs $19.691B Est

Gildan Activewear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIL#NYSE">GIL</a>) narrows FY2025 Adj EPS guidance from $3.38-$3.58 to $3.40-$3.56 vs $3.48 analyst estimate..

Gildan Activewear Narrows FY2025 Adj EPS Guidance from $3.38-$3.58 to $3.40-$3.56 vs $3.48 Est

Canada Goose Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GOOS#NYSE">GOOS</a>) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.62) by 6.45 percent. This is a 14.19 percent decrease over losses of $(0.58) per share from the same period last year. The company reported quarterly sales of $77.879 million which beat the analyst consensus estimate of $68.330 million by 13.97 percent. This is a 20.94 percent increase over sales of $64.397 million the same period last year.

Earnings Misses

GOOS

Canada Goose Hldgs Q1 Adj. EPS $(0.66) Misses $(0.62) Estimate, Sales $77.879M Beat $68.330M Estimate

Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) is looking for Q3 Adj EPS of $1.60-$1.80 vs $1.81 analyst estimate. sees sales of $4.950 billion-$5.100 billion vs $4.928 billion analyst estimate.

Aptiv Sees Q3 Adj EPS $1.60-$1.80 vs $1.81 Est; Sees Sales $4.950B-$5.100B vs $4.928B Est

CSW Industrials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSW#NYSE">CSW</a>) reported quarterly earnings of $2.43 per share which missed the analyst consensus estimate of $2.76 by 11.86 percent. This is a 1.62 percent decrease over earnings of $2.47 per share from the same period last year. The company reported quarterly sales of $263.646 million which missed the analyst consensus estimate of $278.060 million by 5.18 percent. This is a 16.57 percent increase over sales of $226.177 million the same period last year.

CSW Industrials Q1 EPS $2.43 Misses $2.76 Estimate, Sales $263.646M Miss $278.060M Estimate

Utz Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTZ#NYSE">UTZ</a>) lowers FY2025 Adj EPS guidance from $0.85-$0.89 to $0.82-$0.85 vs $0.85 analyst estimate..

Utz Brands Lowers FY2025 Adj EPS Guidance from $0.85-$0.89 to $0.82-$0.85 vs $0.85 Est

XPO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPO#NYSE">XPO</a>) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $1.00 by 5 percent. This is a 6.25 percent decrease over earnings of $1.12 per share from the same period last year. The company reported quarterly sales of $2.08 billion which beat the analyst consensus estimate of $2.06 billion by 1.13 percent. This is a 0.05 percent increase over sales of $2.08 billion the same period last year.

XPO Q2 Adj. EPS $1.05 Beats $1.00 Estimate, Sales $2.08B Beat $2.06B Estimate

Gildan Activewear (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIL#NYSE">GIL</a>) reported quarterly earnings of $0.97 per share which beat the analyst consensus estimate of $0.95 by 1.57 percent. This is a 31.08 percent increase over earnings of $0.74 per share from the same period last year. The company reported quarterly sales of $918.500 million which beat the analyst consensus estimate of $911.417 million by 0.78 percent. This is a 6.53 percent increase over sales of $862.200 million the same period last year.

Gildan Activewear Q2 Adj. EPS $0.97 Beats $0.95 Estimate, Sales $918.500M Beat $911.417M Estimate

Needham analyst Bernie McTernan maintains Fiverr Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FVRR#NYSE">FVRR</a>) with a Buy and lowers the price target from $36 to $32.

FVRR

Needham Maintains Buy on Fiverr Intl, Lowers Price Target to $32

Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) reported quarterly earnings of $2.12 per share which beat the analyst consensus estimate of $1.79 by 18.57 percent. This is a 34.18 percent increase over earnings of $1.58 per share from the same period last year. The company reported quarterly sales of $5.208 billion which beat the analyst consensus estimate of $5.032 billion by 3.51 percent. This is a 3.11 percent increase over sales of $5.051 billion the same period last year.

Aptiv Q2 Adj. EPS $2.12 Beats $1.79 Estimate, Sales $5.208B Beat $5.032B Estimate

Telsey Advisory Group analyst Joseph Feldman maintains Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) with a Market Perform and maintains $2 price target.

COOK

Telsey Advisory Group Maintains Market Perform on Traeger, Maintains $2 Price Target

Xerox Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) sees FY2025 sales of $7.240 billion-$7.360 billion vs $6.209 billion analyst estimate.

Xerox Holdings Sees FY2025 Sales $7.240B-$7.360B vs $6.209B Est

Telsey Advisory Group analyst Dana Telsey maintains VF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VFC#NYSE">VFC</a>) with a Market Perform and maintains $14 price target.

Telsey Advisory Group Maintains Market Perform on VF, Maintains $14 Price Target

MAC Copper Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTAL#NYSE">MTAL</a>, ASX:MAC))) ("MAC" or the "Company") is pleased to announce that the Royal Court of Jersey ("Court") today ordered that meetings of MAC shareholders be held to consider the proposed acquisition of 100% of the issued share capital in MAC by Harmony Gold (Australia) Pty Ltd ("Harmony Australia") (a wholly owned subsidiary of Harmony Gold Mining Company Limited (JSE:HAR, NYSE:HMY) ("Harmony")) by way of a Jersey law scheme of arrangement pursuant to Article 125 of the Companies (Jersey) Law 1991 ("Scheme") (the "Transaction").
Unless otherwise defined, capitalised terms used in this announcement have the meaning given to them in the Scheme Circular (as defined below).
Court orders
The Court has today made orders, among other things, that MAC:
<ul>
<li>convene a meeting of Scheme Shareholders to consider and vote on a resolution to approve the Scheme ("Court Meeting"); and</li>
<li>convene a meeting of MAC Shareholders immediately after the Court Meeting to approve certain other matters in connection with the implementation of the Transaction ("General Meeting").</li>
</ul>
The MAC Directors:
<ul>
<li>continue to unanimously recommend that Scheme Shareholders vote in favour of the Scheme at the Court Meeting and MAC Shareholders vote in favour of the General Meeting Resolution at the General Meeting; and</li>
<li>intend to vote, or cause to be voted, all MAC Shares or MAC CDIs held or controlled by them (totalling 2.44% of the MAC Shares in aggregate) in favour of the Scheme at the Court Meeting and in favour of the General Meeting Resolution at the General Meeting, in each case, in the absence of a Superior Proposal.</li>
</ul>
Scheme Circular
The Court approved the dispatch of a scheme circular, which, among other things, contains full details of the Scheme (the "Scheme Circular"). Dispatch of the Scheme Circular to MAC Shareholders and MAC CDI Holders at the Scheme Voting Record Time is expected to be completed on or about 4 August 2025 as follows:
<ul>
<li>MAC Shareholders will receive a hard copy of the Scheme Circular and Proxy Forms by mail unless they have made an election to receive communications through electronic means, in which case they will receive an electronic copy;</li>
<li>MAC CDI Holders will receive a hard copy of the Scheme Circular and CDI Voting Instruction Forms by mail unless they have made an election to receive communications through electronic means, in which case they will receive an electronic copy; and</li>
<li>other beneficial holders will receive a hard copy of the Scheme Circular and any other voting instruction forms by mail or an electronic copy based on the elections made with the Intermediary that holds MAC Shares on their behalf.</li>
</ul>
A copy of the Scheme Circular is attached to this announcement and is also available for viewing on MAC's website at <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.maccopperlimited.com&amp;esheet=54300052&amp;newsitemid=20250730628270&amp;lan=en-US&amp;anchor=www.maccopperlimited.com&amp;index=1&amp;md5=ddd82b68e80f5b0378d8cbdcc0c5efa5">www.maccopperlimited.com</a>.
MAC Securityholders should read the Scheme Circular carefully, and in its entirety, including the materials accompanying it, before deciding how to vote at the Court Meeting and the General Meeting.
If, after reading the Scheme Circular, you have any questions about the Scheme or the Scheme Circular, please contact MAC's proxy solicitation firm, Sodali &amp; Co, at:
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">If you are a MAC Shareholder Call toll-free in US: +1 (800) 662-5200 Outside of US: +1 (203) 658-9400</td>
<td colspan="1" rowspan="1">If you are a MAC CDI Holder Within Australia: 1300 229 418 Outside Australia: +61 2 9066 4059</td>
</tr>
</tbody>
</table>
</figure>
 &nbsp;

Legal

MTAL

MAC Copper Moves Closer to Harmony Gold Deal After Jersey Court Approves Shareholder Meetings

TC Energy (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TRP#TSX">TRP</a>) reported quarterly earnings of $0.82 per share which beat the analyst consensus estimate of $0.70 by 17.14 percent. This is a 3.8 percent increase over earnings of $0.79 per share from the same period last year. The company reported quarterly sales of $3.744 billion which beat the analyst consensus estimate of $3.152 billion by 18.78 percent. This is a 8.35 percent decrease over sales of $4.085 billion the same period last year.

TSX:TRP

TC Energy Q2 Adj. EPS $0.82 Beats $0.70 Estimate, Sales $3.744B Beat $3.152B Estimate

Press Releases

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

Contracts

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

AI & Tech Breakout: PRSO, IPA, NEHC, SOAR Lead Today's Innovation Surge – More Movers Inside

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

Markets

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

CGTL

HCTI

KLTO

MTWO

NEHC

PNPNF

PRSO

RSLS

SNYR

SOAR

TSX:TIXT

TSXV:PNPN

Aethlon Medical

Autonomix Medical

Baird Medical Investment Holdings Ltd - Warrant

Baird Medical Investment

Bluejay Diagnostics

Biomerica

Co-Diagnostics

Alpha Tau Medical

Ekso Bionics Holdings, Inc. - Common Stock

Ekso Bionics Holdings

GlucoTrack

HeartSciences

Helius Medical Technologies, Inc. - Class A Common Stock

Helius Medical Tech

Intelligent Bio Solutions Inc. - Common Stock

Intelligent Bio Solutions

INVO Fertility

NanoVibronix

ENDRA Life Sciences

Nuwellis

PAVmed

Predictive Oncology

SINTX Technologies

Strata Skin Sciences, Inc. - Common Stock

Strata Skin Sciences

Tivic Health Systems, Inc. - Common stock

Tivic Health Systems

Tenon Medical

Venus Concept

Catheter Precision

Xylo Technologies Ltd. - American Depositary Shares

Comments

Reshape Lifesciences

Vendite allo scoperto

Reshape Lifesciences (NASDAQ:RSLS) Azioni, Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO